Ratings GoHealth, Inc.

Equities

GOCO

US38046W2044

Delayed Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
10.15 ^USD	+1.40%		-3.33%	-23.91%

03-20	RBC Cuts Price Target on GoHealth to $13 From $20, Notes 'Diminished Topline Visibility' in Near Term; Sector Perform Kept	MT
03-14	GoHealth Shares Tumble After Surprise Q4 Loss, Revenue Miss	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Multiline Insurance & Brokers

	1st Jan change	Capi.	ESG Refinitiv
GOHEALTH, INC.	-23.91%	101M	D+
AON PLC	-2.06%	61.97B	C
ARTHUR J. GALLAGHER & CO.	+4.10%	51.16B	B-
WILLIS TOWERS WATSON PUBLIC LIMITED COMPANY	+4.04%	25.66B	C+
BROWN & BROWN, INC.	+14.55%	23.24B	C
CAIXA SEGURIDADE PARTICIPAÇÕES S.A.	+20.54%	9.56B	-
RYAN SPECIALTY HOLDINGS, INC.	+13.76%	5.81B	-
STEADFAST GROUP LIMITED	-2.41%	4.02B	B
AUB GROUP LIMITED	+3.24%	1.99B	C+
BRP GROUP, INC.	+11.16%	1.76B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes